Long Term Results after 3 Courses of ABVD plus Subtotal Nodal Radiotherapy in 188 Adult Patients with Stage I, II and IIIA Hodgin Lymphoma

Pauline Brice,Irène Biasoli,C Hennequin,Marc André,Patricia Franchi-Rezgui

doi:10.4137/cmbd.s357

Abstract

In patients with Hodgkin lymphoma (HL) a continued improvement in outcome with a high cure rate is observed but with an increased treatment-induced late effects. We report the long-term results from 188 (stage I to IIIA) patients treated during the period 1985-94 with 3 courses of ABVD-like chemotherapy and subtotal nodal radiotherapy. 10 year overall survival is of 88% and no secondary leukaemia was observed. The main long term toxicity was cardiac, mainly related to a mediastinal dose of 45 Grays in patients with partial remission. New strategies are aiming to reduce the mediastinal dose at 30 Grays after chemotherapy-induced complete remission.

Highlights

In patients with Hodgkin lymphoma (HL) a continued improvement in outcome with a high cure rate is observed but with an increased treatment-induced late effects
Most of these studies used chemotherapy with MOPP or COPP/ABVD, combinations which may be associated with severe toxicities and the use of ABVD with STNI improved the disease-free survival over STNI alone [18] but no data on survival were avalaible with a short followup
Results are close to those of a randomized study with similar patients where ABVD was superior to regimen without alkylating agents [19]

Summary

Introduction

In patients with Hodgkin lymphoma (HL) a continued improvement in outcome with a high cure rate is observed but with an increased treatment-induced late effects. We report the long-term results from 188 (stage I to IIIA) patients treated during the period 1985–94 with 3 courses of ABVD-like chemotherapy and subtotal nodal radiotherapy. 10 year overall survival is of 88% and no secondary leukaemia was observed. The main long term toxicity was cardiac, mainly related to a mediastinal dose of 45 Grays in patients with partial remission. New strategies are aiming to reduce the mediastinal dose at 30 Grays after chemotherapy-induced complete remission

Objectives

Methods

Conclusion